glp-1 agonists and retained gastric contents at endoscopy Frontiers SMALL STUDY LOOKS AT HOLDING
Description
Learn how they work, how they differ, whether they can be combined, and what side effects to watch for.
The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.
What is Retatrutide
Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users
See if you qualify for compensation and how to file.
